Super Memory Cycle: Net Profit of ¥28.7 Billion Is Only the Surface

The essence of Risk #3: Module manufacturers earn profits from the temporary window of 'replacing Chinese memory chips'; CXMT earns profits from the time gap afforded by its 'EUV-free path'—neither is sustainable. 03. The Real Battlefield: CXMT + ChangXin Technology—China’s Dual Experiment The confluence of ice and fire marks China’s memory industry’s 'dual experiment'. Experiment One: Sustainability of the EUV-Free Path Without EUV lithography tools, CXMT has opted for a DUV multiple-patterning + etch compensation process flow—a 'second-best solution' validated as viable between 2022 and 2026. Yet this path carries costs: yield is 15–25% lower than the EUV path (industry-estimated range; exact figures subject to disclosure in CXMT’s prospectus), and depreciation cost per wafer is 20–30% higher. In other words, CXMT trades money for time and yield for capacity. How long can this strategy last? ● If the U.S. does not further restrict DUV equipment upgrades between 2026 and 2027, CXMT can maintain an 18–24-month technology gap behind the three global leaders at the DDR5/LPDDR5 nodes. ● If the U.S. further restricts licensing for multi-layer DUV exposure applications, this gap will widen further, delaying CXMT’s HBM breakthrough timeline accordingly (the extent of delay depends on the specifics of DUV upgrade restrictions—no definitive numbers yet available). Key decision window: Q4 2026 – H1 2027, when the U.S. Department of Commerce may issue new DUV restriction rules. Experiment Two: HBM—from Zero to One CXMT’s core strategic goal for 2026 is achieving mass production of HBM—going from zero to one. ● If HBM3E enters mass production before H1 2027—even with only 50% yield—it could generate significant annualized incremental revenue for the company within China’s domestic substitution window (rough order-of-magnitude estimate based on industry HBM pricing and production scale; this section presents a speculative range—exact figures subject to official company disclosures). ● If HBM remains stuck in R&D beyond H1 2027, CXMT’s valuation logic must shift back from a 'cyclical stock' to a 'growth stock', representing a structural headwind for ChangXin Technology’s market capitalization. This is the single most critical variable for CXMT’s stock price before H1 2027. External Variable: SK Hynix’s U.S. Factory—How Much Time Does It Leave for China? On August 28, 2026, SK Hynix broke ground on its HBM manufacturing base in West Lafayette, Indiana, USA (Source: SK Hynix official website http://news.skhynix.com, August 28, 2026). Timeline: ● June 10, 2026: SK Hynix listed on Nasdaq, raising over USD 26 billion (Source: multiple media outlets) ● August 19, 2026: SK Hynix announced a KRW 40 trillion share buyback and cancellation program, raising shareholder returns to over 50% of free cash flow (Source: SK Hynix official announcement)

U.S. SPAC Market Dynamics in August 2025

U.S. SPAC Market Dynamics: August 1–15, 2025 I. SPAC Acquisitions 1. BOXABL On August 5, 2025, Boxabl Inc., a leader in innovative housing solutions, and FG Merger II Corp. (Nasdaq: FGMC), a special purpose acquisition company (SPAC) listed on the Nasdaq Stock Market, announced they have entered into a definitive merger agreement. Upon completion, the combined company is expected to continue trading on the Nasdaq under the ticker symbol 'BXBL'. BOXABL is revolutionizing the housing market through its modular construction system, aiming to deliver affordable, high-quality homes at unprecedented speed. Founded in 2017, the company has drawn global attention with its innovative approach to solving housing challenges for individuals and communities. 2. Presidio On August 5, 2025, Presidio Investment Holdings, LLC (“PIH”), a differentiated oil & gas operator focused on optimizing mature U.S. hydrocarbon production assets, and EQV Ventures Acquisition Corp. (NYSE: EQV), a SPAC sponsored by the experienced oil & gas acquisition and operations firm EQV Group, announced they have entered into a definitive business combination agreement. Upon closing, Presidio will become a publicly traded company, expected to list on the New York Stock Exchange under the ticker symbol 'FTW'. Headquartered in Fort Worth, Texas, Presidio is a leading operator of mature oil & gas wells in the Mid-Continent region, focusing on optimizing existing production capacity to generate sustainable cash flow from low-decline assets. 3. PCM On August 6, 2025, Parataxis Holdings LLC, a leading institutional-grade digital asset management platform founded by partners of Parataxis Capital Management LLC (“PCM”), announced it has entered into a definitive business combination agreement with SilverBox Corp IV (NYSE: SBXD), a publicly listed SPAC sponsored by an affiliate of SilverBox Capital LLC and initiated by SilverBox Sponsor IV. Upon completion of the proposed transaction, the combined company will be named Parataxis Holdings Inc. and is expected to trade on the New York Stock Exchange (“NYSE”) under the ticker symbol 'PRTX'. PCM is a multi-strategy investment management firm focused on digital assets, founded in 2019. It manages several merged hedge fund products and provides segregated advisory services to institutional allocators, family offices, funds-of-funds, and high-net-worth individuals. Parataxis Holdings is a subsidiary of PCM, dedicated to BTC treasury and other digital asset investment opportunities.

Balchem Corp Revenue Breakdown – BX:BL9B

Jul 28, 2026

Balchem Corp reported 822.23M CHF annual revenue, driven by its Human Nutrition and Health segment (522.74M CHF). The U.S. was the top geographic market, contributing 602.07M CHF.

TradingView

2026-03-22

BCPC SEC Filings - Balchem Corp 10-K, 10-Q, 8-K Forms

2026-03-27

Balchem Reports €0.0 Million NonCurrent Deferred Revenue as of December 2025

2026-04-09

Balchem Corp. Stock Valuation Revised Amid Competitive FMCG Landscape

2026-04-11

Balchem Reports $581 Million Gross Property, Plant and Equipment as of December 2025

2026-04-16

Zinc Methionine Chelates Market Forecast Report 2025-2033 Featuring Alltech, Balchem, Titan Biotech, UNO VETCHEM, Zinpro, Chaitanya Biologicals, Chengdu Chelation Biology, JH, Novus, Priya